Projects per year
Personal profile
Biography
Dr Tran is currently appointed to the level of Adjunct Clinical Professor. He is Head of Haemostasis Thrombosis Unit and Director of the Haemophilia Treatment Centre (a state-wide service) at Alfred Health. The Alfred is a dynamic academic research organisation that is involved with basic science research and works to translate and integrate best evidence into routine standard of care, often in collaboration with The Australian Centre for Blood Diseases (ACBD) Monash University. Alfred Health is one of the premier organisations that thrives on delivering best care to complex patients.
Dr Tran is an active member of several research organisations, including the Haematology Clinical Research Unit (CRU), ACBD, Monash University, Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ), and Australian Haemophilia Centres Directors’ Organisation (AHCDO). He has particular interests in the management of congenital haemophilia, venous thromboembolism (VTE) and its complications, rare bleeding disorders, immune platelet disorders and novel therapeutics. He has been the principal investigator for over 80 clinical trials in VTE diagnosis and management, haemophilia, and immune thrombocytopenia. He continues to supervise PhD (5), Master Phil (1), and numerous advanced haematology trainees.
He has a strong interest in standardising best practice and has led several published guidelines supported by specialty organisations in Australia, New Zealand and Asia Pacific regions. He is a strong supporter of medical education, training advanced haematology trainees (>30) and was a committee member of the Written Examination committee, Royal Australian College of Physicians (2008-15). He believes in the need to improve care in establishing countries and has lectured widely in the Asia-Pacific region, as well as, working with world federations societies for specific diseases. He is extremely active in AHCDO and THANZ, where he is the current Chair and Chair of the Clinical Trials Group (CTG) respectively. He works with governmental departments advisory boards and disease-specific advocacy groups to advocate for novel therapies to improve patient outcomes. He has a proven track record for leadership not only within Alfred Health but the wider community of haematology.
Related Links:
Clinical activities
Clinical focus & Service Provision
Diagnostic testing and treatment for patients with hereditary bleeding disorders began in 1954, and was incorporated into duties and service delivery from the laboratory haematology department. Services were redeveloped following the retirement of Dr Sawers and recognition of HIV infection in plasma recipients in 1984. It was subsequently recognised by the Department of Health as adult state centre for management of patients with hereditary bleeding disorders offering a multidisciplinary model of care that encompasses the diagnosis, treatment and long-term follow up. Currently, we are the only international haemophilia training centre in Australia.
The RSHC won the Twinning Centre of the year in 2013 by the World Federation of Haemophilia for educational work with the National Institute of Haematology and Blood Transfusion, Hanoi, Vietnam. Today approximately 1100 patients are registered with the centre and the number continues to rise. Prof Tran has led over 40 clinical trials since 2007.
Our comprehensive service includes Haemophilia and other hereditary bleeding disorders allowing the effective delivery of both inpatient and outpatient care.
We provide a consultative service to other specialties within The Alfred hospital. Patients are also referred to us for treatment from numerous centres within Melbourne and regional Victoria
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Haematology, FRACP, Royal Australasian College of Physicians (RACP)
Award Date: 1 Jan 2003
Haematology, FRCPA, Royal College of Pathologists of Australasia (RCPA)
Award Date: 1 Jan 2003
External positions
Chair, Australian Haemophilia Clinical Directors Organisation (AHCDO)
1 Nov 2017 → …
Chair, Clinical Trials Group, Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ)
1 Apr 2015 → …
Director, Haemophilia Treatment Centre, Alfred Health
1 Feb 2012 → …
President, Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ)
1 Nov 2011 → 1 Oct 2013
Medical Director, Laboratory Haematology, Monash Health
1 Feb 2010 → 1 Jan 2012
Head, Haemostasis Thrombosis Services, Alfred Hospital
1 Dec 2009 → …
Thrombosis Research Fellow, McMaster University
16 Oct 2003 → 1 Dec 2005
Research area keywords
- Thrombosis
- Haematology
Collaborations and top research areas from the last five years
-
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies
Tran, H. (Primary Chief Investigator (PCI))
8/10/24 → 8/03/26
Project: Research
-
Antithrombotic therapy to ameliorate clinical complications in community acquired pneumonia (ATTACC-CAP)
McQuilten, Z. (Primary Chief Investigator (PCI)), Tong, S. Y. C. (Chief Investigator (CI)), Webb, S. (Chief Investigator (CI)), Higgins, L. (Chief Investigator (CI)), Ryan, L. (Chief Investigator (CI)), Venkatesh, B. (Chief Investigator (CI)), Roberts, J. A. (Chief Investigator (CI)), Tran, H. (Chief Investigator (CI)), Zarychanski, R. (Chief Investigator (CI)), McFadyen, J. (Chief Investigator (CI)), Aung, A. K. (Chief Investigator (CI)), Lawler, P. (Chief Investigator (CI)), Winearls, J. R. (Chief Investigator (CI)) & Burrell, A. (Chief Investigator (CI))
1/07/24 → 30/06/28
Project: Research
-
A phase 2 study to evaluate the efficacy and safety of ianalumab (VAY736) in patients with primary immune thrombocytopenia (ITP) previously treated with at least a corticosteroid and a thrombopoietin receptor agonist (TPO-RA)
Tran, H. (Primary Chief Investigator (PCI)) & Malherbe, M. (Project Manager)
8/09/23 → 7/09/25
Project: Research
-
A Global, Open-label Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Hemophilia B With Inhibitors
Tran, H. (Primary Chief Investigator (PCI)) & Malherbe, M. (Project Manager)
3/09/23 → 2/09/25
Project: Research
-
A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
Tran, H. (Primary Chief Investigator (PCI))
22/08/23 → 22/08/25
Project: Research
-
Efficacy and Long-Term Outcomes of Eltrombopag Treatment Within 6 Months of Diagnosis in Patients With Steroid Unresponsive or Dependent Immune Thrombocytopenia
Tran, H., Dix, C., Bird, R., Chunilal, S., Brighton, T., Reynolds, J., He, S., Mazis, C. & Grigg, A., Mar 2025, In: American Journal of Hematology. 100, 3, p. 516-519 4 p.Research output: Contribution to journal › Letter › Research › peer-review
Open Access -
Attention to the risk of venous thromboembolism in mechanically restrained hospitalised patients
Chee, A., Bortz, H., Izrailov, E. & Tran, H., Nov 2024, In: Internal Medicine Journal. 54, 11, p. 1923-1924 2 p.Research output: Contribution to journal › Letter › Other › peer-review
-
Erratum to ‘Illustrated State-of-the-Art Capsules of the ISTH 2024 Congress’ [Research and Practice in Thrombosis and Haemostasis Volume 8, Issue 4, May 2024, 102432](S2475037924001213)(10.1016/j.rpth.2024.102432)
Ward, C., Curry, N., El-Ekiaby, M., Jurk, K., Versteeg, H. H., Keragala, C., Burstyn-Cohen, T., Antoniak, S., Suzuki, Y., Baker, R. I., Christophe, O., Revel-Vilk, S., Hart, A., Deppermann, C., Tran, H., Pozzi, N., Kahr, W. H. A., Grover, S. P., Wenzel, P. & Brown, A. C. & 13 others, , Jul 2024, In: Research and Practice in Thrombosis and Haemostasis. 8, 5, 2 p., 102498.Research output: Contribution to journal › Comment / Debate › Other › peer-review
Open Access -
Exploring the effects of Factor Xa inhibitors on thrombin generation in people with haemophilia
Dix, C., McFadyen, J. D. & Tran, H. A., May 2024, In: Thrombosis Research. 237, p. 148-153 6 p.Research output: Contribution to journal › Article › Research › peer-review
2 Citations (Scopus) -
Illustrated State-of-the-Art Capsules of the ISTH 2024 Congress
Ward, C., Curry, N., El-Ekiaby, M., Jurk, K., Versteeg, H. H., Keragala, C., Burstyn-Cohen, T., Antoniak, S., Suzuki, Y., Baker, R. I., Christophe, O., Revel-Vilk, S., Hart, A., Deppermann, C., Tran, H., Pozzi, N., Kahr, W. H. A., Grover, S. P., Wenzel, P. & Brown, A. C. & 11 others, , May 2024, In: Research and Practice in Thrombosis and Haemostasis. 8, 4, 32 p., 102432.Research output: Contribution to journal › Article › Other › peer-review
Open Access4 Citations (Scopus)
Prizes
Activities
-
Congress of the International-Society-on-Thrombosis-and-Haemostasis (ISTH)
Huyen Tran (Member of programme committee)
2024Activity: Participating in or organising an event types › Contribution to conference
-
COVID-19 national taskforce, Hospital and Acute care committee
Huyen Tran (Member)
2023Activity: External Academic Engagement › Committees and working groups
-
BLOOD ANNUAL CONFERENCE
Huyen Tran (Invited speaker)
2023Activity: Participating in or organising an event types › Contribution to conference
-
Australian Haemophilia Centres Directors’ Organisation
Huyen Tran (Chair/ Co-Chair)
2023Activity: External Academic Engagement › Committees and working groups
-
Chair, Clinical Trials Group (CTG),
Huyen Tran (Chair/ Co-Chair)
2023Activity: External Academic Engagement › Professional association or peak discipline body
Press/Media
-
Thrombotic Thrombocytopenia Syndrome associated with AstraZeneca COVID-19 vaccine
7/07/21
1 Media contribution
Press/Media: Research